Prospective Lifespan Cohort of Myocardial Infarction

NCT07471763 | Not Yet Recruiting

• 1 other identifier: K2026-03-001
• Study Type: observational
• Target: 6,000
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management. The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up. The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.

Conditions

Acute Myocardial Infarction (AMI); Stable Angina; Unstable Angina

Keywords

prospective cohort; multi-omics; artificial intelligence; risk prediction; precision medicine; acute myocardial infarction; lifespan cohort

Outcome Measures

Primary Outcomes (1)

• Rate of all-cause mortality

  From enrollment to the end of study follow-up, up to 5 years

Secondary Outcomes (7)

• Rate of cardiovascular death

  From enrollment to the end of study follow-up, up to 5 years

• Rate of recurrent myocardial infarction

  From enrollment to the end of study follow-up, up to 5 years

• Rate of readmission due to heart failure

  From enrollment to the end of study follow-up, up to 5 years

• Rate of target vessel or non-target vessel revascularization

  From enrollment to the end of study follow-up, up to 5 years

• Rate of stroke

  From enrollment to the end of study follow-up, up to 5 years

Study Arms (2)

High-risk Population

Participants at high risk of acute myocardial infarction, including individuals with stable angina or unstable angina, with or without silent myocardial ischemia, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up.

Confirmed Acute Myocardial Infarction Population

Participants with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction, including type 1, 2, 3, 4a, 4b, 4c, and 5 myocardial infarction, as well as myocardial infarction with non-obstructive coronary arteries when applicable, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up.

Eligibility Criteria

• Age: 18 Years - 74 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults aged 18 to 74 years will be enrolled into two cohorts: a high-risk population cohort including individuals with stable angina or unstable angina, and a confirmed acute myocardial infarction cohort including patients diagnosed according to the Fourth Universal Definition of Myocardial Infarction. All participants must be able to provide informed consent and complete baseline assessment, biospecimen collection, and longitudinal follow-up.

You may qualify if:

• Age 18 to 74 years
• Diagnosed with stable angina, unstable angina, or acute myocardial infarction
• For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized
• Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction
• Willing to participate and able to provide written informed consent
• Able to complete baseline assessment, biospecimen collection, and long-term follow-up

You may not qualify if:

• End-stage malignant tumor with expected survival of less than 1 year
• Severe hepatic or renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m² or Child-Pugh class C)
• Active autoimmune disease or long-term use of immunosuppressive agents
• Pregnant or breastfeeding women
• Inability to provide informed consent or severe cognitive impairment
• Previous participation in another clinical study that may conflict with this project
• Any other condition considered by the investigators to make participation inappropriate

Sponsors & Collaborators

• Fujian Provincial Hospital: lead

Study Sites (1)

Fuzhou University Affiliated Provincial Hospital

Fuzhou, Fujian, 350001, China

Location

MeSH Terms

Conditions

Angina, Stable; Angina, Unstable

Condition Hierarchy (Ancestors)

Angina Pectoris; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Chest Pain; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Kaiyang Lin, PhD

  Fuzhou University Affiliated Provincial Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Kaiyang Lin, PhD

CONTACT

+86 13559355708; lky7411@sina.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator, Department of Cardiology

Study Record Dates

• First Submitted: March 10, 2026
• First Posted: March 13, 2026
• Study Start: April 10, 2026
• Primary Completion (Estimated): April 10, 2031
• Study Completion (Estimated): April 10, 2031
• Last Updated: March 25, 2026

Record last verified: 2026-03

Locations

CN (1)